SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company...
PDUFA Action Date for the Arimoclomol NDA is September 21, 2024CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics,...
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and...
LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ -- Anivive Lifesciences Inc, a One Health technology company today announced that the National...
BEVERLY, Mass., Aug. 2, 2024 /PRNewswire/ -- Carrier Global Corporation, on behalf of its Sensitech business, a world leader in...
Thermobalancing therapy with Dr Allen's Device treats chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) effectively and safely, helping to...
Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to...
High-validity RWE company welcomes Cheifetz and Melmed PALO ALTO, Calif., Aug. 1, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity...
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass.,...
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...